Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.

• Wondering whether Novavax at about US$7.98 is a bargain or a value trap? This article walks through the key signals that matter for you.

• The stock has had a mixed run, with a 2.0% decline over the last week and a 20.0% decline over the last month. It still shows returns of 11.9% year to date and 26.5% over the past year, set against an 11.7% annualised decline over three years and a 95.9% drop over five years.

• Recent attention on Novavax has been shaped by ongoing interest in vaccine players and how they fit into broader healthcare themes. This helps explain why the share price has seen sharp moves over different time…